Better Therapeutics Inc (NASDAQ:BTTX) marked $0.21 per share on Friday, up from a previous closing price of $0.17. While Better Therapeutics Inc has overperformed by 23.60%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BTTX fell by -85.21%, with highs and lows ranging from $1.61 to $0.14, whereas the simple moving average fell by -72.87% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
On November 24, 2021, Chardan Capital Markets started tracking Better Therapeutics Inc (NASDAQ: BTTX) recommending Buy.
Analysis of Better Therapeutics Inc (BTTX)
In order to gain a clear picture of Better Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -1021.64% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.57, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.60M can be a very valuable indicator of volatility for BTTX stock. On a monthly basis, the volatility of the stock is set at 12.67%, whereas on a weekly basis, it is put at 16.56%, with a gain of 39.07% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.25, showing growth from the present price of $0.21, which can serve as yet another indication of whether BTTX is worth investing in or should be passed over.
How Do You Analyze Better Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 50.83%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 5.31% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in BTTX shares?
The recent increase in stakes in BTTX appears to be a result of several institutional investors and hedge funds increasing their positions. The company now owns 1,583,079 shares of the stock, with a value of $0.22 million, following the purchase of 1,583,079 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in BTTX during the first quarter, upping its stake by 14.01%. During the last quarter, the company dropped down 61,418 additional shares for a total stake of worth $70985.0, bringing number of shares owned by the company to 499,897.
During the first quarter, Geode Capital Management LLC subtracted a -14,846 position in BTTX. BlackRock Fund Advisors sold an additional 1365.0 shares in the last quarter, decreasing its holdings by -1.53%, now holding 87912.0 shares worth $12484.0. At the end of the first quarter, SSgA Funds Management, Inc. increased its BTTX holdings by 29.65% and now holds 58600.0 BTTX shares valued at $8321.0 with the added 13400.0 shares during the period. BTTX shares are owned by institutional investors to the tune of 5.31% at present.
